BDBM275915 US10071974, Example 26::US10071974, Example 27::US10071974, Example 28::US10577336, Example 28

SMILES Cn1nc(c2ccccc12)C(C)(C)NC(=O)C1CCNCCO1

InChI Key InChIKey=CGVZXSHTMUZGJV-UHFFFAOYSA-N

Data  6 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 275915   

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  61.3nMpH: 7.4 T: 2°CAssay Description:Compounds are dissolved and diluted in DMSO. The final test solution contains 1% DMSO. The cAMP standard (Lance cAMP 384 Kit; PerkinElmer, Cat# AD026...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  55.8nMpH: 7.4 T: 2°CAssay Description:Compounds are dissolved and diluted in DMSO. The final test solution contains 1% DMSO. The cAMP standard (Lance cAMP 384 Kit; PerkinElmer, Cat# AD026...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  48.4nMpH: 7.4 T: 2°CAssay Description:Compounds are dissolved and diluted in DMSO. The final test solution contains 1% DMSO. The cAMP standard (Lance cAMP 384 Kit; PerkinElmer, Cat# AD026...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  61.3nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  55.8nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM275915(US10071974, Example 27 | US10071974, Example 28 | ...)
Affinity DataEC50:  48.4nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
Go to US Patent